The University of Chicago Header Logo

Connection

Ardaman Shergill to Humans

Back to Details
This is a "connection" page, showing publications Ardaman Shergill has written about Humans.
Ardaman Shergill
Connection Strength
0.328
Humans
  1. Multi-Institutional Study Evaluating the Role of Circulating Tumor DNA in the Management of Appendiceal Cancers. JCO Precis Oncol. 2024 May; 8:e2300531.
    View in: PubMed
    Score: 0.030
  2. Colorectal Cancer: Genetic Underpinning and Molecular Therapeutics for Precision Medicine. Genes (Basel). 2024 04 25; 15(5).
    View in: PubMed
    Score: 0.030
  3. Utility of Circulating Tumor DNA Assessment in Characterizing Recurrence Sites after Optimal Resection for Metastatic Colorectal Cancer. J Am Coll Surg. 2024 Jun 01; 238(6):1013-1020.
    View in: PubMed
    Score: 0.030
  4. Investigating the Use of Circulating Tumor DNA in Early-Stage Colon Cancer. Oncology (Williston Park). 2022 10 07; 36(10):620-626.
    View in: PubMed
    Score: 0.027
  5. Diagnostic Challenges due to a Germline Missense MSH2 Variant in a Patient With Immunotherapy-Responsive Locally Advanced Rectal Adenocarcinoma. Cancer Rep (Hoboken). 2024 Dec; 7(12):e70037.
    View in: PubMed
    Score: 0.008
  6. Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors. N Engl J Med. 2025 Feb 13; 392(7):653-665.
    View in: PubMed
    Score: 0.008
  7. Mutational Features and Tumor Microenvironment Alterations in High-Grade Appendiceal Cancers Treated With Iterative Hyperthermic Intraperitoneal Chemotherapy. JCO Precis Oncol. 2024 Sep; 8:e2400149.
    View in: PubMed
    Score: 0.008
  8. Alliance A022104/NRG-GI010: The Janus Rectal Cancer Trial: a randomized phase II/III trial testing the efficacy of triplet versus doublet chemotherapy regarding clinical complete response and disease-free survival in patients with locally advanced rectal cancer. BMC Cancer. 2024 Jul 26; 24(1):901.
    View in: PubMed
    Score: 0.008
  9. Improved Survival With Adjuvant Cyclooxygenase 2 Inhibition in PIK3CA-Activated Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance). J Clin Oncol. 2024 08 20; 42(24):2853-2859.
    View in: PubMed
    Score: 0.008
  10. Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study. J Clin Oncol. 2024 Aug 20; 42(24):2918-2927.
    View in: PubMed
    Score: 0.008
  11. A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results. Nat Med. 2024 Apr; 30(4):1013-1022.
    View in: PubMed
    Score: 0.008
  12. Radiation Therapy Quality Assurance Analysis of Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Pancreas. Int J Radiat Oncol Biol Phys. 2024 Sep 01; 120(1):111-119.
    View in: PubMed
    Score: 0.008
  13. Alliance for clinical trials in Oncology (Alliance) trial A022101/NRG-GI009: a pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer: evaluating radiation, ablation, and surgery (ERASur). BMC Cancer. 2024 Feb 13; 24(1):201.
    View in: PubMed
    Score: 0.007
  14. ASO Visual Abstract: Fragmentation of Care in Patients with Peritoneal Metastases Undergoing Cytoreductive Surgery. Ann Surg Oncol. 2024 01; 31(1):657-658.
    View in: PubMed
    Score: 0.007
  15. Early Integrated Palliative Care Within a Surgical Oncology Clinic. JAMA Netw Open. 2023 11 01; 6(11):e2341928.
    View in: PubMed
    Score: 0.007
  16. ASO Author Reflections: Fragmented Care in Patients with Peritoneal Metastases. Ann Surg Oncol. 2024 01; 31(1):655-656.
    View in: PubMed
    Score: 0.007
  17. Fragmentation of Care in Patients with Peritoneal Metastases Undergoing Cytoreductive Surgery. Ann Surg Oncol. 2024 Jan; 31(1):645-654.
    View in: PubMed
    Score: 0.007
  18. Pan-Cancer Prevalence of Microsatellite Instability-High (MSI-H) Identified by Circulating Tumor DNA and Associated Real-World Clinical Outcomes. JCO Precis Oncol. 2023 09; 7:e2300118.
    View in: PubMed
    Score: 0.007
  19. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet. 2023 07 01; 402(10395):41-53.
    View in: PubMed
    Score: 0.007
  20. Doublet vs. Triplet Systemic Chemotherapy for High Grade Appendiceal Adenocarcinoma with Peritoneal Metastases. J Gastrointest Surg. 2023 11; 27(11):2560-2562.
    View in: PubMed
    Score: 0.007
  21. Preoperative Treatment of Locally Advanced Rectal Cancer. N Engl J Med. 2023 Jul 27; 389(4):322-334.
    View in: PubMed
    Score: 0.007
  22. Role of Tumor-informed Personalized Circulating Tumor DNA Assay in Informing Recurrence in Patients With Peritoneal Metastases From Colorectal and High-grade Appendix Cancer Undergoing Curative-intent Surgery. Ann Surg. 2023 12 01; 278(6):925-931.
    View in: PubMed
    Score: 0.007
  23. Association of Inflammatory Biomarkers With Survival Among Patients With Stage III Colon Cancer. JAMA Oncol. 2023 03 01; 9(3):404-413.
    View in: PubMed
    Score: 0.007
  24. Brief Report: Discordance Between Liquid and Tissue Biopsy-Based Next-Generation Sequencing in Lung Adenocarcinoma at Disease Progression. Clin Lung Cancer. 2023 05; 24(3):e117-e121.
    View in: PubMed
    Score: 0.007
  25. PI3K Pathway Alterations in Peritoneal Metastases are Associated with Earlier Recurrence in Patients with Colorectal Cancer Undergoing Optimal Cytoreductive Surgery. Ann Surg Oncol. 2023 May; 30(5):3114-3122.
    View in: PubMed
    Score: 0.007
  26. Mutational profiles and prognostic impact in colorectal and high-grade appendiceal adenocarcinoma with peritoneal metastases. J Surg Oncol. 2023 Apr; 127(5):831-840.
    View in: PubMed
    Score: 0.007
  27. Survival in Total Preoperative vs. Perioperative Chemotherapy for Patients with Metastatic High-Grade Appendiceal Adenocarcinoma Undergoing CRS/HIPEC. J Gastrointest Surg. 2022 12; 26(12):2591-2594.
    View in: PubMed
    Score: 0.007
  28. Detection of microsatellite instability-high (MSI-H) by liquid biopsy predicts robust and durable response to immunotherapy in patients with pancreatic cancer. J Immunother Cancer. 2022 06; 10(6).
    View in: PubMed
    Score: 0.007
  29. Celecoxib and Myrtol: A Novel Therapy for Recurrent Appendiceal Mucinous Neoplasms With Extensive Peritoneal Dissemination. Am J Clin Oncol. 2022 01 01; 45(1):9-13.
    View in: PubMed
    Score: 0.006
  30. DNA Double-strand Break Signaling Is a Therapeutic Target in Head and Neck Cancer. Anticancer Res. 2021 Nov; 41(11):5393-5403.
    View in: PubMed
    Score: 0.006
  31. Guide to Enhanced Recovery for Cancer Patients Undergoing Surgery: ERAS for Patients Undergoing Cytoreductive Surgery with or Without HIPEC. Ann Surg Oncol. 2021 Nov; 28(12):6955-6964.
    View in: PubMed
    Score: 0.006
  32. Novel Application of Iterative Hyperthermic Intraperitoneal Chemotherapy for Unresectable Peritoneal Metastases from High-Grade Appendiceal Ex-Goblet Adenocarcinoma. Ann Surg Oncol. 2021 Mar; 28(3):1777-1785.
    View in: PubMed
    Score: 0.006
  33. A multi-institutional comparison of mitoxantrone, etoposide, and cytarabine vs high-dose cytarabine and mitoxantrone therapy for patients with relapsed or refractory acute myeloid leukemia. Am J Hematol. 2020 08; 95(8):937-943.
    View in: PubMed
    Score: 0.006
  34. Outcome Disparities in Caucasian and Non-Caucasian Patients With Myeloproliferative Neoplasms. Clin Lymphoma Myeloma Leuk. 2016 Jun; 16(6):350-7.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.